Clinical Trial Update: Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of MK-2206 in locally advanced or metastatic solid tumors completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasms
• Solid Tumors
• Tumors

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Locally Advanced Tumors, Metastatic Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2019-04-01